Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study

Abstract

Long-term BLV monotherapy is safe and effectively decreases HDV-RNA and ALT-even in patients with cirrhosis. The optimal duration of BLV treatment alone or in combination with PEG-IFN remains to be established. An algorithm for a response-guided BLV treatment approach is proposed.